"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
- Patient Information:
Details with Side Effects
Single 10 mg doses of SYMLIN (pramlintide acetate injection) (83 times the maximum dose of 120 mcg) were administered to three healthy volunteers. Severe nausea was reported in all three individuals and was associated with vomiting, diarrhea, vasodilatation, and dizziness. No hypoglycemia was reported. SYMLIN (pramlintide acetate injection) has a short half-life and in the case of overdose, supportive measures are indicated.
SYMLIN (pramlintide acetate injection) is contraindicated in patients with any of the following:
- a known hypersensitivity to SYMLIN (pramlintide acetate injection) or any of its components, including metacresol;
- a confirmed diagnosis of gastroparesis;
- hypoglycemia unawareness.
Last reviewed on RxList: 4/9/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Symlin Information
Symlin - User Reviews
Symlin User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.